{"id":"NCT01892163","sponsor":"Moorfields Eye Hospital NHS Foundation Trust","briefTitle":"Multicentre Randomised Clinical Trial Comparing Fixed vs Pro re Nata (PRN) Dosing of 700 μg Dexamethasone","officialTitle":"A Multicentre Prospective Open-label Randomised Clinical Trial Comparing the Efficacy of Fixed Versus PRN Dosing of 700 μg Dexamethasone Posterior Segment Drug Delivery System (Ozurdex) in Patients With Refractory Diabetic Macular Oedema","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-03","primaryCompletion":"2014-12","completion":"2014-12","firstPosted":"2013-07-04","resultsPosted":"2017-02-23","lastUpdate":"2017-02-23"},"enrollment":100,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Macular Edema"],"interventions":[{"type":"DEVICE","name":"Ozurdex","otherNames":["Dexamethasone"]}],"arms":[{"label":"Ozurdex PRN dosing","type":"ACTIVE_COMPARATOR"},{"label":"Ozurdex fixed dosing","type":"EXPERIMENTAL"}],"summary":"Multicentre randomized controlled trial to evaluate whether 5 monthly fixed dosing of 700 µg Dexamethasone Posterior Segment Drug Delivery System (Ozurdex) is as efficacious as Optical coherence tomography (OCT)-guided PRN dosing in patients with refractory diabetic macular edema.","primaryOutcome":{"measure":"The Difference Between Arms in the Change From Baseline in Best Corrected Visual Acuity at 12 Months","timeFrame":"Baseline and 12 months","effectByArm":[{"arm":"Ozurdex PRN Dosing","deltaMin":0,"sd":13},{"arm":"Ozurdex Fixed Dosing","deltaMin":0.53,"sd":16.1}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":50},"commonTop":["Raised Intraocular Pressure","cataract progresion","vitreous haemorrhage"]}}